Johanna Schaffenrath1,2, Tania Wyss3,4, Liqun He5, Elisabeth Jane Rushing6, Mauro Delorenzi3,4, Flavio Vasella1, Luca Regli1, Marian Christoph Neidert1, Annika Keller1,2. 1. Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zürich, Zürich University, Zürich, Switzerland. 2. Neuroscience Center Zürich, University of Zürich and ETH Zürich, Zürich, Switzerland. 3. Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Lausanne, Switzerland. 4. Department of Oncology, University of Lausanne, Lausanne, Switzerland. 5. Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. 6. Institute of Neuropathology, University Hospital Zürich, Zürich, Switzerland.
Abstract
BACKGROUND: Brain tumors, whether primary or secondary, have limited therapeutic options despite advances in understanding driver gene mutations and heterogeneity within tumor cells. The cellular and molecular composition of brain tumor stroma, an important modifier of tumor growth, has been less investigated to date. Only few studies have focused on the vasculature of human brain tumors despite the fact that the blood-brain barrier (BBB) represents the major obstacle for efficient drug delivery. METHODS: In this study, we employed RNA sequencing to characterize transcriptional alterations of endothelial cells (EC) isolated from primary and secondary human brain tumors. We used an immunoprecipitation approach to enrich for EC from normal brain, glioblastoma (GBM), and lung cancer brain metastasis (BM). RESULTS: Analysis of the endothelial transcriptome showed deregulation of genes implicated in cell proliferation, angiogenesis, and deposition of extracellular matrix (ECM) in the vasculature of GBM and BM. Deregulation of genes defining the BBB dysfunction module was found in both tumor types. We identified deregulated expression of genes in vessel-associated fibroblasts in GBM. CONCLUSION: We characterize alterations in BBB genes in GBM and BM vasculature and identify proteins that might be exploited for developing drug delivery platforms. In addition, our analysis on vessel-associated fibroblasts in GBM shows that the cellular composition of brain tumor stroma merits further investigation.
BACKGROUND: Brain tumors, whether primary or secondary, have limited therapeutic options despite advances in understanding driver gene mutations and heterogeneity within tumor cells. The cellular and molecular composition of brain tumor stroma, an important modifier of tumor growth, has been less investigated to date. Only few studies have focused on the vasculature of human brain tumors despite the fact that the blood-brain barrier (BBB) represents the major obstacle for efficient drug delivery. METHODS: In this study, we employed RNA sequencing to characterize transcriptional alterations of endothelial cells (EC) isolated from primary and secondary human brain tumors. We used an immunoprecipitation approach to enrich for EC from normal brain, glioblastoma (GBM), and lung cancer brain metastasis (BM). RESULTS: Analysis of the endothelial transcriptome showed deregulation of genes implicated in cell proliferation, angiogenesis, and deposition of extracellular matrix (ECM) in the vasculature of GBM and BM. Deregulation of genes defining the BBB dysfunction module was found in both tumor types. We identified deregulated expression of genes in vessel-associated fibroblasts in GBM. CONCLUSION: We characterize alterations in BBB genes in GBM and BM vasculature and identify proteins that might be exploited for developing drug delivery platforms. In addition, our analysis on vessel-associated fibroblasts in GBM shows that the cellular composition of brain tumor stroma merits further investigation.
Authors: Philip Dusart; Björn Mikael Hallström; Thomas Renné; Jacob Odeberg; Mathias Uhlén; Lynn Marie Butler Journal: Cell Rep Date: 2019-11-05 Impact factor: 9.423
Authors: Eleanor B Carson-Walter; Jessica Hampton; Eveline Shue; Daniel M Geynisman; Pramod Kumar Pillai; Ramasri Sathanoori; Stephen L Madden; Ronald L Hamilton; Kevin A Walter Journal: Clin Cancer Res Date: 2005-11-01 Impact factor: 12.531
Authors: Joanna Kalucka; Laura P M H de Rooij; Jermaine Goveia; Katerina Rohlenova; Sébastien J Dumas; Elda Meta; Nadine V Conchinha; Federico Taverna; Laure-Anne Teuwen; Koen Veys; Melissa García-Caballero; Shawez Khan; Vincent Geldhof; Liliana Sokol; Rongyuan Chen; Lucas Treps; Mila Borri; Pauline de Zeeuw; Charlotte Dubois; Tobias K Karakach; Kim D Falkenberg; Magdalena Parys; Xiangke Yin; Stefan Vinckier; Yuxiang Du; Robert A Fenton; Luc Schoonjans; Mieke Dewerchin; Guy Eelen; Bernard Thienpont; Lin Lin; Lars Bolund; Xuri Li; Yonglun Luo; Peter Carmeliet Journal: Cell Date: 2020-02-13 Impact factor: 41.582
Authors: Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger Journal: Lancet Oncol Date: 2016-06-03 Impact factor: 41.316
Authors: Elizabeth A Kuczynski; Peter B Vermeulen; Francesco Pezzella; Robert S Kerbel; Andrew R Reynolds Journal: Nat Rev Clin Oncol Date: 2019-08 Impact factor: 66.675